AMAG Pharmaceuticals, Inc. Announces Presentation of Positive Results from Phase III Studies of Feru

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today announced positive results from pooled data from three open-label, multicenter, randomized Phase III trials of ferumoxytol as an intravenous iron replacement therapeutic. The data is being presented today at approximately 6:00 pm ET as a poster at the 49th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia. The poster is available on the Company’s web site at www.amagpharma.com.
The poster, “Treatment of Iron-Deficiency Anemia with IV Ferumoxytol in CKD Patients: Efficacy Compared with Oral Iron across Different Age Groups” presents results from 885 dialysis dependent and non-dialysis dependent patients with chronic kidney disease (CKD). Patients received either two doses of 510 mg of intravenous (IV) ferumoxytol within one week or 200 mg of oral iron daily for three weeks and were followed for 35 days. The pooled data demonstrated a statistically significant achievement of the primary endpoint in patients treated with ferumoxytol compared to those treated with oral iron.

full article >> http://www.pr-usa.net/index.php?option=com_content&task=view&id=51212&Itemid=9